Determining Prognosis and Treatment

Current medical society guidelines rely on cancer stage to determine treatment for lung cancer, including early-stage non-small cell lung adenocarcinoma. Classification of lung cancer by stage is based primarily on the size and location of the tumor and serves as an indicator of disease progression. However, cancer stage alone does not reveal the aggressiveness of the tumor. In fact, two patients with the same lung cancer stage may have very different estimates of mortality risk if tumor aggressiveness is taken into account.1,2,3

Using Prognostic Testing to Personalize Lung Cancer Treatment

Myriad myPlan® Lung Cancer is a molecular prognostic test that measures the expression of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness.1,2,3,4 For patients with early-stage non-small cell lung adenocarcinoma, the Myriad myPlan Lung Cancer score combines both gene expression and pathological stage to better predict the five-year risk of lung adenocarcinoma-specific mortality. Gaining insight into tumor aggressiveness can help determine if surgery alone is sufficient, or if more aggressive treatment is needed.*

Learn more about Myriad myPlan Lung Cancer


*Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

1. Wistuba II, Behrens C, Lombardi F, et al. Prognostic Marker in Early Stage Lung Adenocarcinoma. Clinical Cancer Research. November 15, 2013 19:6261-6271

2. Bueno R, et al. Validation of a molecular and pathological model for fiver-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015; 10:67-73.

3. Rakha E, et al. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. Eur J Cancer 2015; 51:1897-1903

4. Whitfield ML, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2001;13:1977-2000.